Vaccinex Inc (VCNX)
OTHER OTC:VCNX
Want to see VCNX full AI Analyst Report?
VCNX Stock Chart & Stats
$0.69
-$0.04(-3.99%)
At close: 4:00 PM EST
$0.69
-$0.04(-3.99%)
Day’s Range― - ―
52-Week Range$0.31 - $1.50
Previous CloseN/A
Volume245.00
Average Volume (3M)1.22K
Market Cap
$3.08M
Enterprise Value$1.86M
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.48
Shares Outstanding2,676,637
10 Day Avg. Volume776
30 Day Avg. Volume1,224
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.83
Price to Sales (P/S)3.42
P/FCF Ratio-0.13
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit3.24
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Monoclonal Antibody PlatformOwning a proprietary monoclonal antibody platform and a lead clinical asset (VAC-1) provides durable R&D leverage. A validated platform can enable pipeline expansion, attract partnerships or licensing, and create long-term value if clinical progress continues.
Diverse Non-dilutive Funding ChannelsAccess to grants, partnerships, milestone payments and future royalties reduces sole dependence on equity raises. Persistent non-dilutive and partnership funding enhances runway and supports sustained development spending without immediate shareholder dilution.
Positive Revenue TrendA year-over-year revenue increase, even modest, signals improving commercial or collaboration traction. For a biotech, reproducible revenue growth from grants or partnerships suggests operational progress and a foundation for scaling funding sources over the medium term.
Bears Say
Negative Stockholders' EquityNegative equity is a structural solvency concern that limits borrowing capacity and increases refinancing risk. It can force dilutive capital raises, constrain strategic flexibility, and deter potential partners or acquirers unless corrected by sustained profit or recapitalization.
Persistent Cash Burn And Reliance On FinancingOngoing negative operating and free cash flow implies the company requires external financing to fund operations. Reliance on financing inflows creates execution risk if markets tighten, and increases probability of dilution or unfavorable financing terms over the medium term.
Sustained Negative ProfitabilityProlonged negative net income and poor EBIT margins undermine internal capital generation and long-term viability without external funding. Continued unprofitability can restrict R&D investment, hamper ability to scale, and elevate investor scrutiny over strategy execution.
Vaccinex News
VCNX FAQ
What was Vaccinex Inc’s price range in the past 12 months?
Vaccinex Inc lowest stock price was $0.31 and its highest was $1.50 in the past 12 months.
What is Vaccinex Inc’s market cap?
Vaccinex Inc’s market cap is $3.08M.
When is Vaccinex Inc’s upcoming earnings report date?
Vaccinex Inc’s upcoming earnings report date is Nov 16, 2026 which is in 180 days.
How were Vaccinex Inc’s earnings last quarter?
Currently, no data Available
Is Vaccinex Inc overvalued?
According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued.
Does Vaccinex Inc pay dividends?
Vaccinex Inc does not currently pay dividends.
What is Vaccinex Inc’s EPS estimate?
Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex Inc have?
Vaccinex Inc has 2,676,637 shares outstanding.
What happened to Vaccinex Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaccinex Inc?
Currently, no hedge funds are holding shares in VCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaccinex Inc
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
―
Insiders
―
Mutual Funds
6.13% Other Institutional Investors
93.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---